Published in Bioorg Med Chem Lett on January 05, 2004
Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels. Radiology (2011) 1.59
Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimers. Mol Imaging Biol (2006) 1.46
Heterobivalent ligands crosslink multiple cell-surface receptors: the human melanocortin-4 and delta-opioid receptors. Angew Chem Int Ed Engl (2008) 1.36
Synthesis and evaluation of bivalent NDP-alpha-MSH(7) peptide ligands for binding to the human melanocortin receptor 4 (hMC4R). Bioconjug Chem (2007) 1.31
Enhanced targeting with heterobivalent ligands. Mol Cancer Ther (2009) 1.21
Rigid linkers for bioactive peptides. Bioconjug Chem (2006) 1.19
Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances. Adv Drug Deliv Rev (2012) 1.18
Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer. Mol Cancer Ther (2008) 1.10
Solid-Phase Synthesis of Heterobivalent Ligands Targeted to Melanocortin and Cholecystokinin Receptors. Int J Pept Res Ther (2008) 1.02
Cell-specific targeting by heterobivalent ligands. Bioconjug Chem (2011) 1.00
Design, synthesis, and validation of a branched flexible linker for bioactive peptides. J Org Chem (2007) 0.98
Computational insights into the interactions between DNA and siRNA with "rigid" and "flexible" triazine dendrimers. Biomacromolecules (2010) 0.95
Heterobivalent ligands target cell-surface receptor combinations in vivo. Proc Natl Acad Sci U S A (2012) 0.94
Discovery of high-affinity protein binding ligands--backwards. PLoS One (2010) 0.93
Synthesis and evaluation of dimeric derivatives of 5-HT(2A) receptor (5-HT(2A)R) antagonist M-100907. ACS Chem Neurosci (2011) 0.92
A solanesol-derived scaffold for multimerization of bioactive peptides. J Org Chem (2010) 0.91
A sucrose-derived scaffold for multimerization of bioactive peptides. Bioorg Med Chem (2011) 0.90
Potent agonists of the protease activated receptor 2 (PAR2). J Med Chem (2011) 0.90
Specificity and mobility of biomacromolecular, multivalent constructs for cellular targeting. Biomacromolecules (2007) 0.89
Development of melanoma-targeted polymer micelles by conjugation of a melanocortin 1 receptor (MC1R) specific ligand. J Med Chem (2011) 0.89
Development of homomultimers and heteromultimers of lung cancer-specific peptoids. Biopolymers (2011) 0.85
Trigonal scaffolds for multivalent targeting of melanocortin receptors. Org Biomol Chem (2015) 0.79
Hetero-bivalent GLP-1/glibenclamide for targeting pancreatic β-cells. Chembiochem (2013) 0.79
Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016. Biochim Biophys Acta (2017) 0.78
Glioblastoma targeting via integrins is concentration dependent. Biotechnol Bioeng (2009) 0.75
Synthesis and bioactivity of MSH4 oligomers prepared by an A2 + B2 strategy. Tetrahedron Lett (2015) 0.75
Synthesis and evaluation of bivalent ligands for binding to the human melanocortin-4 receptor. Bioorg Med Chem (2014) 0.75
Development of Follicle-Stimulating Hormone Receptor Binding Probes to Image Ovarian Xenografts. J Biotechnol Biomater (2015) 0.75
Why do cancers have high aerobic glycolysis? Nat Rev Cancer (2004) 20.60
A microenvironmental model of carcinogenesis. Nat Rev Cancer (2008) 4.40
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol (2006) 3.98
Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res (2006) 3.90
Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res (2009) 3.40
Adaptive therapy. Cancer Res (2009) 2.81
Radiomics: the process and the challenges. Magn Reson Imaging (2012) 2.65
Acidity generated by the tumor microenvironment drives local invasion. Cancer Res (2013) 2.63
The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc Natl Acad Sci U S A (2003) 2.29
Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia (2005) 2.17
Tumor pH and its measurement. J Nucl Med (2010) 2.08
Renal and systemic pH imaging by contrast-enhanced MRI. Magn Reson Med (2003) 2.05
High resolution pH(e) imaging of rat glioma using pH-dependent relaxivity. Magn Reson Med (2006) 1.97
Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol (2007) 1.94
Antinociceptive and nociceptive actions of opioids. J Neurobiol (2004) 1.93
The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasion. Cancer Res (2009) 1.92
Hitting multiple targets with multimeric ligands. Expert Opin Ther Targets (2004) 1.86
Responsive MRI agents for sensing metabolism in vivo. Acc Chem Res (2009) 1.84
Imaging pH and metastasis. NMR Biomed (2011) 1.67
Lanthanide-based time-resolved fluorescence of in cyto ligand-receptor interactions. Anal Biochem (2004) 1.66
Contributions of cell metabolism and H+ diffusion to the acidic pH of tumors. Neoplasia (2003) 1.63
Stability of FDG-PET Radiomics features: an integrated analysis of test-retest and inter-observer variability. Acta Oncol (2013) 1.62
Metabolic changes during carcinogenesis: potential impact on invasiveness. J Theor Biol (2006) 1.59
Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol (2003) 1.57
Quantitative imaging in cancer evolution and ecology. Radiology (2013) 1.55
Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther (2005) 1.54
Parallel synthesis and biological evaluation of different sizes of bicyclo[2,3]-Leu-enkephalin analogues. Biopolymers (2005) 1.54
Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia (2005) 1.54
Lateral phase separation in lipid-coated microbubbles. Langmuir (2006) 1.52
Of cancer and cave fish. Nat Rev Cancer (2011) 1.50
Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain (2005) 1.49
Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia (2005) 1.45
Acid treatment of melanoma cells selects for invasive phenotypes. Clin Exp Metastasis (2008) 1.44
Sweat but no gain: inhibiting proliferation of multidrug resistant cancer cells with "ersatzdroges". Int J Cancer (2014) 1.44
Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm (2011) 1.42
Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem (2006) 1.40
Imaging the extracellular pH of tumors by MRI after injection of a single cocktail of T1 and T2 contrast agents. NMR Biomed (2011) 1.40
Determining suitable internal standards for mRNA quantification of increasing cancer progression in human breast cells by real-time reverse transcriptase polymerase chain reaction. Anal Biochem (2005) 1.38
Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents. Biochem Pharmacol (2003) 1.38
Chronic autophagy is a cellular adaptation to tumor acidic pH microenvironments. Cancer Res (2012) 1.38
Peptidomimetics, a synthetic tool of drug discovery. Curr Opin Chem Biol (2008) 1.37
Automated Delineation of Lung Tumors from CT Images Using a Single Click Ensemble Segmentation Approach. Pattern Recognit (2013) 1.36
Multiscale modelling of vascular tumour growth in 3D: the roles of domain size and boundary conditions. PLoS One (2011) 1.36
Heterobivalent ligands crosslink multiple cell-surface receptors: the human melanocortin-4 and delta-opioid receptors. Angew Chem Int Ed Engl (2008) 1.36
A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep (2013) 1.33
Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. Neoplasia (2002) 1.32
Synthesis and evaluation of bivalent NDP-alpha-MSH(7) peptide ligands for binding to the human melanocortin receptor 4 (hMC4R). Bioconjug Chem (2007) 1.31
Systemic buffers inhibit carcinogenesis in TRAMP mice. J Urol (2012) 1.28
Synthesis and investigations of double-pharmacophore ligands for treatment of chronic and neuropathic pain. Bioorg Med Chem (2009) 1.28
Development of a lanthanide-based assay for detection of receptor-ligand interactions at the delta-opioid receptor. Anal Biochem (2005) 1.25
Rhodopsin reconstituted into a planar-supported lipid bilayer retains photoactivity after cross-linking polymerization of lipid monomers. J Am Chem Soc (2005) 1.24
Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia (2008) 1.23
Thermostability of firefly luciferases affects efficiency of detection by in vivo bioluminescence. Mol Imaging (2004) 1.23
Synthesis and evaluation of 3-aminopropionyl substituted fentanyl analogues for opioid activity. Bioorg Med Chem Lett (2006) 1.23
A stimulus-responsive contrast agent for ultrasound molecular imaging. Biomaterials (2007) 1.22
Development of novel enkephalin analogues that have enhanced opioid activities at both mu and delta opioid receptors. J Med Chem (2007) 1.21
Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokinin-1 receptor antagonists. J Med Chem (2007) 1.21
Reduction of metastasis using a non-volatile buffer. Clin Exp Metastasis (2011) 1.21
Enhanced targeting with heterobivalent ligands. Mol Cancer Ther (2009) 1.21
Multiple N-methylation of MT-II backbone amide bonds leads to melanocortin receptor subtype hMC1R selectivity: pharmacological and conformational studies. J Am Chem Soc (2010) 1.20
Evolutionary dynamics of cancer prevention. Nat Rev Cancer (2010) 1.20
Rigid linkers for bioactive peptides. Bioconjug Chem (2006) 1.19
Expression-driven reverse engineering of targeted imaging and therapeutic agents. Expert Opin Ther Targets (2003) 1.19
Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings. Clin Nucl Med (2013) 1.19
Evolutionary approaches to prolong progression-free survival in breast cancer. Cancer Res (2012) 1.19
Phosphatidylethanolamine enhances rhodopsin photoactivation and transducin binding in a solid supported lipid bilayer as determined using plasmon-waveguide resonance spectroscopy. Biophys J (2004) 1.17
Blockade of melanocortin transmission inhibits cocaine reward. Eur J Neurosci (2005) 1.17
The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging. Clin Cancer Res (2005) 1.17
Novel 3D pharmacophore of alpha-MSH/gamma-MSH hybrids leads to selective human MC1R and MC3R analogues. J Med Chem (2005) 1.16
DNA and polylysine adsorption and multilayer construction onto cationic lipid-coated microbubbles. Langmuir (2007) 1.16
Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem (2006) 1.16
Understanding the structural requirements of 4-anilidopiperidine analogues for biological activities at mu and delta opioid receptors. Bioorg Med Chem Lett (2007) 1.15
Gold nanorods targeted to delta opioid receptor: plasmon-resonant contrast and photothermal agents. Mol Imaging (2008) 1.15
Solution structures of cyclic melanocortin agonists and antagonists by NMR. Biopolymers (2003) 1.14
Redox-sensitive contrast agents for MRI based on reversible binding of thiols to serum albumin. Magn Reson Med (2006) 1.14
MRI-measured water mobility increases in response to chemotherapy via multiple cell-death mechanisms. NMR Biomed (2007) 1.14
Lanthanide-based luminescent assays for ligand-receptor interactions. Life Sci (2005) 1.13
Neuropathic pain is maintained by brainstem neurons co-expressing opioid and cholecystokinin receptors. Brain (2008) 1.13
Animal anaesthesia for in vivo magnetic resonance. NMR Biomed (2003) 1.11
Targeting the metabolic microenvironment of tumors. Adv Pharmacol (2012) 1.11
Promise and progress for functional and molecular imaging of response to targeted therapies. Pharm Res (2007) 1.11
Direct observation of G-protein binding to the human delta-opioid receptor using plasmon-waveguide resonance spectroscopy. J Biol Chem (2003) 1.11
Characterization of breast cancers and therapy response by MRS and quantitative gene expression profiling in the choline pathway. NMR Biomed (2009) 1.10
Design, synthesis, and biological studies of efficient multivalent melanotropin ligands: tools toward melanoma diagnosis and treatment. J Med Chem (2011) 1.10
Noninvasive detection of breast cancer lymph node metastasis using carbonic anhydrases IX and XII targeted imaging probes. Clin Cancer Res (2011) 1.10
Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer. Mol Cancer Ther (2008) 1.10
Structure-activity studies of the melanocortin peptides: discovery of potent and selective affinity antagonists for the hMC3 and hMC4 receptors. J Med Chem (2002) 1.09
Development of potent μ and δ opioid agonists with high lipophilicity. J Med Chem (2010) 1.08